Indivior Share Discussion Threads

[steeplejack] 06/3/2023 23:38

The UK equity market(as pointed out by numerous broad sheet articles of late)is becoming a secondary market in a global context.The FTSE 100 is comprised of a multiplicity of stocks that trade more extensively in the US than London.What with the march of private equity,the increasing competition of overseas stockmarkets and the inability to attract new listings let alone retain the existing ones,the LSE is under real pressure.Brexit hasn't helped the cause.Indivior is one of many who have taken the opportunity to seek a wider investment audience in the USA.Indivior could be a highly prized takeover candidate.The fly in the ointment is the litigation issue of course.Not insurmountable perhaps.

[ricky46] 06/3/2023 16:09

The Nasdaq listing will

[dealy] 06/3/2023 10:50

not sure what is going to get this moving up again

[florenceorbis] 05/3/2023 09:17

Support maintained at 1504p

[misca2] 27/2/2023 08:47

Support still maintained at 1510p

[glasgow13] 27/2/2023 08:45

sarkasm thanks

[glasgow13] 27/2/2023 08:36

How long has the buy back got to go?

[waldron] 22/2/2023 21:48

1510.00 GBX

[casholaa] 22/2/2023 21:46

I'd say well below 1500p, even if it takes a breather

[grupo guitarlumber] 21/2/2023 09:43

Strong support at 1544p

[steeplejack] 21/2/2023 09:33

Looks like the market is toying with the idea of putting the stock back into a trading range of £14-£16 that persisted for 6 months between April 22 to Oct 22.

[littleton2] 18/2/2023 08:47

Starting to look good.

[redbaron10] 17/2/2023 09:50

Sold out here six months ago but back in now.Results were really positive despite the millions put aside for liabilities.There is always an element of worst case scenario with many of these legal cases but ever since this was hived off from Reckitt there's been this cloud.If you accept the risk this has big potential going forward imho.Addictions and their sufferers will always need help sadly.

[youngers] 16/2/2023 15:07

I think the provision is likely linked to the US listing. That would have caused extra auditor scrutiny of judgements particularly around provision v contingent liability. As you say not great but the underlying financial performance and prospects remain positive

[gregmorg] 16/2/2023 14:28

well, I listened to the webcast today and am relaxed re the financials and significant progress made. The next couple of years look positively exciting for added revenue and additional product hopes. But, I am not pleased at all with the added provision for mis selling although we were aware there were a few legacy issues to be settled. I guess there was no way to gently prepare the market. Yet it is what it is and we will see how things develop from here.

[liam1om] 16/2/2023 11:43

Good point steelplejack. UK media goes into a frenzy when energy companies make a large profit but are completely silent when big pharma companies make a fortune on the back of peoples suffering.

[steeplejack] 16/2/2023 10:38

Its interesting.It's regarded as unacceptable that energy companies enjoy a profits bonanza on the back of higher oil/gas prices induced by the Russian/Ukraine conflict.Perhaps it could only be a small step before society regards bumper revenues generated on the back of treating a drug addiction pandemic as questionable.Western societies are struggling to identify a suitable 'moral' code in so many aspects of modern life.

[waldron] 16/2/2023 10:23

4interest




Panel backs moving opioid antidote Narcan over the counter

By MATTHEW PERRONEyesterday


FILE - Attendees practice administering Narcan during an overdose education and Narcan training class at the Onala Recovery Center on the South Shore of Pittsburgh on Monday, Dec. 13, 2021. U.S. health advisers are weighing whether the overdose-reversal drug, Narcan, should be made available as an over-the-counter medication to help fight the national opioid crisis. A panel of experts to the Food and Drug Administration will vote on the switch late Wednesday, Feb. 15, 2023 following hours of presentations and discussions on whether untrained users can follow the instructions to use the antidote in emergency situations. (Alexandra Wimley/Pittsburgh Post-Gazette via AP, File)

[steeplejack] 16/2/2023 09:43

It wasn't an 'unknown'.The market chose to believe that the DOJ settlement might be an end to litigation but frankly that was naive.We're dealing with lawyers here and they smell blood in the water.At one point in todays statement,Indivior refers to some who 'purport' to represent plaintiffs.There are clearly a lot of lawyers sniffing an easy meal here.The trial won't happen until September but i sense the company is actively seeking a settlement through mediation.The company is doing so well that cash flow from operations can fund any likely legal settlement but its going to overshadow the ADR listing unfortunately.

[casholaa] 16/2/2023 09:33

Yes, 'spooks' the market as it were unknown. What else, if anything, is lurking?

[villarich] 16/2/2023 09:18

This will have spooked the market given previous litigation issues. I don't see it as having as material an impact as the problems from years ago but can understand why Mr Market has reacted this way. I'm up over 5x original stake and happy to sit on my position.

[babbler] 16/2/2023 08:56

Initial mediation sessions in late January 2023 regarding legacy civil multidistrict antitrust litigation provided the Group with new information on the previously disclosed contingent liability. Accordingly, the Group recorded an exceptional provision of $290m in FY 2022. Because these matters are in various stages, Indivior cannot predict with any certainty how these matters will ultimately be resolved, or the costs, or timing of such resolution. In particular, any final aggregate costs of these matters, whether resolved by settlement or trial, may be materially different from this provision. The Group cannot predict with any certainty whether it will reach settlement with the antitrust claimants (refer to Note 12 for further information).

[steeplejack] 16/2/2023 08:46

Litigation.....That's why the stock is down.Lawyers,sharks and parasites.This latest round of legal aggro resulted in meetings with plaintiffs in Jan 2023 although things have clearly been bubbling for awhile.The trading performance is up to expectations.Shame this should crop up ahead of the ADR listing.Might well dampen interest.Company must be more than irritated.(Oh and the group's investment portfolio has suffered from a preponderance of treasuries).